Search

Displaying results 4061 - 4070 of 8698 in total
  1. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    Efonidipine is a calcium channel blocker of the dihydropyridine class, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, Landel. The drug has been shown to block T-type in addition to ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  2. Drug

    Solriamfetol

    go.drugbank.com/drugs/DB14754
    ApprovedInvestigational

    Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive ...

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  3. Drug

    Brimapitide

    go.drugbank.com/drugs/DB15231
    Investigational

    Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).

  4. Drug

    Citicoline

    go.drugbank.com/drugs/DB12153
    ApprovedInvestigationalWithdrawn

    It has been investigated for the treatment, supportive care, and diagnosis of Mania, Stroke, Hypomania, Cocaine Abuse, and Bipolar Disorder, among others.

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  5. Drug

    Veru-111

    go.drugbank.com/drugs/DB16462
    Investigational

    VERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360.

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    Serabelisib

    go.drugbank.com/drugs/DB14935
    Investigational

    Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics

  7. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis. … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.

    Categories: GABA-B Receptor Agonists
  8. Drug

    Human interferon beta

    go.drugbank.com/drugs/DB14999
    ApprovedInvestigational

    It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.[A191733,L12012] … [A191784] Interferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus.

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    catabolism via monoamine oxidase (MAO) inhibition and address symptoms. … [A253697,L43672] Before the approval of this gene therapy, the treatment options for patients with AADC deficiency were limited to attempts to increase monoamine neurotransmitter production, decrease neurotransmitter

  10. Drug

    Ibudilast

    go.drugbank.com/drugs/DB05266
    Investigational

    (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume

    Categories: Drugs for Obstructive Airway Diseases